Literature DB >> 15162894

Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin.

Ann K Wittkowsky1, Kelly S Whitely, Emily Beth Devine, Edith Nutescu.   

Abstract

STUDY
OBJECTIVES: Because the risk of major bleeding associated with warfarin increases with increasing international normalized ratio (INR) as well as with advanced age, we evaluated the association between age and INR in patients with major bleeding events related to anticoagulation with warfarin.
DESIGN: Retrospective record review.
SETTING: Two university-affiliated anticoagulation clinics. PATIENTS: Sixty-six patients (mean age 61.2 yrs, range 21-90 yrs) receiving warfarin therapy who experienced major bleeding, defined as bleeding requiring hospitalization, during a 20-month index period.
MEASUREMENTS AND MAIN RESULTS: In patients aged 65 years or older, the mean INR at the time of a major bleeding event was significantly lower than that in patients younger than 65 years (INR 3.1 vs 4.2, respectively; p=0.01). For every 1-year increase in age, mean INR at the time of a major bleeding event decreased by 0.03 (p=0.02).
CONCLUSION: Patients aged 65 years or older experience warfarin-related major bleeding events at a mean INR 1.1 units lower (95% confidence interval -1.9 to -0.27) than patients younger than 65 years. Older patients may require more aggressive management of overanticoagulation to minimize the risk of major bleeding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15162894     DOI: 10.1592/phco.24.6.600.34735

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

Review 1.  Pharmacogenetics of warfarin dosing in patients of African and European ancestry.

Authors:  Aditi Shendre; Chrisly Dillon; Nita A Limdi
Journal:  Pharmacogenomics       Date:  2018-10-22       Impact factor: 2.533

2.  To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort.

Authors:  Serena Granziera; Giulia Bertozzo; Vittorio Pengo; Lucia Marigo; Gentian Denas; Florinda Petruzzellis; Katia Rossi; Tiziana Infante; Seena Jose Padayattil; Egle Perissinotto; Enzo Manzato; Giovanni Nante
Journal:  Intern Emerg Med       Date:  2015-04-21       Impact factor: 3.397

3.  Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.

Authors:  Nianjun Liu; Marguerite R Irvin; Degui Zhi; Amit Patki; T Mark Beasley; Deborah A Nickerson; Charles E Hill; Jinbo Chen; Stephen E Kimmel; Nita A Limdi
Journal:  Pharmacogenomics       Date:  2017-07-07       Impact factor: 2.533

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.